---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000118"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T22:52:11.123058+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent settles Janssen COVID vaccine manufacturing dispute; receives $50M

## Summary
- Janssen will pay Emergent $50M by July 31, 2024 under settlement agreement.
- Settlement resolves all claims and arbitration related to MSA for Ad26.COV2-S vaccine.
- Parties exchange broad releases covering affiliates, officers, and directors.
- Ends previously disclosed arbitration between Emergent and Janssen.

## SEC filing metadata
- accession: 0001367644-24-000118
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000118/0001367644-24-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000118/ebs-20240703.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000118
- JSON: https://secwatch.observer/filing/0001367644-24-000118.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.